DURECT Corp. DRRX:NASDAQ

www.thelifesciencesreport.com Review:

The Life Sciences Report - Biotech and Life Sciences stock coverage from experts- learn to invest in biotech and life sciences stocks - Insight, analysis and ideas about life sciences investments from the best experts in the biotech and life sciences industry

http://www.thelifesciencesreport.com/pub/htdocs/exclusive.html Streetwise Interviews - The Gold Report Read what analysts and experts are saying about the gold sector.

http://www.thelifesciencesreport.com/pub/dir/13 The Life Sciences Report - The Alliance for Regenerative Medicine (ARM)'s mission is to advance regenerative medicine by representing, supporting and engaging all stakeholders in the field, including companies, academic research institutions, patient advocacy groups, foundations, health insurers, financial institutions and other organizations.Based in Washington, D.C., ARM is a global advocacy organization that promotes legislative, regulatory, reimbursement, investment, technical and other initiatives to accelerate the development of safe and effective regenerative medicine technologies. ARM also works to increase public understanding of the field and its potential to transform human healthcare. “ For the past several years, The Life Sciences Report (TLSR) has served as a major proponent of the Alliance for Regenerative Medicine (ARM) and our members. Their unique formula for reaching investors, both institutional and retail, via in-depth interviews, has helped educate the investor community and propel growth in the regenerative medicine sector. We feel TLSR's commitment to quality content is a constant consideration in everything they do, and their combination of information and insight is a unique feature not found anywhere else. We value our continued partnership with TLSR, proudly support their activities and greatly appreciate their on-going endorsement of ARM and our members. ” —Alliance for Regenerative Medicine

http://www.thelifesciencesreport.com/pub/dir/14 The Life Sciences Report - Neurotechnology Industry Organization is a global trade association representing companies involved in neuroscience (drugs, software, device, diagnostics), brain research institutes and patient advocacy groups.

http://www.thelifesciencesreport.com/pub/na/exploring-solutions-to-healthcares-spending-crisis Exploring Solutions to Healthcares Spending Crisis - Rising healthcare costs continue to preoccupy providers, patients, politicians and investors. Some cost increases stem from inefficiencies in the medical system, some from social and demographic trends, and others are a function of profit motives on the part of insurers and a few drug companies. In this article for The Life Sciences Report, Dr. Len Yaffe of Stoc*Doc Partners reviews the issues and proposes some cures.

http://www.thelifesciencesreport.com/pub/na/analysts-keep-focus-on-durects-dur-928 Analysts Keep Focus on DURECTs DUR-928 - The FDA's recent Complete Response Letter for Remoxy, which is licensed by DURECT to Pain Therapeutics, has not changed the view of several analysts who follow DURECT. They are focused on DUR-928 for NASH and impaired kidney function, indications that are of great interest to Big Pharma.

http://www.thelifesciencesreport.com/pub/na/viveves-treatment-for-improving-womens-sexual-function-may-leapfrog-the-competition Viveves Treatment for Improving Womens Sexual Function May Leapfrog the Competition [VIVE] - Private-pay aesthetic procedures constitute a trend in medical devices, according to Anthony Vendetti, Director of Research at Maxim Group. These nonreimbursable types of procedures have seen rapid growth in the past decade. In this interview with The Life Sciences Report, Vendetti discusses Viveve Medical, which is attempting to leapfrog the competition to get FDA approval to use its patented radiofrequency technology to improve women's sexual function.

http://www.thelifesciencesreport.com/pub/na/stock-moving-catalysts-anticipated-for-regeneus-in-q4-16 Stock-Moving Catalysts Anticipated for Regeneus in Q4/16 [RGS] - Australian regenerative medicine company Regeneus Ltd. has a handful of stock-moving Q4/16 catalysts on the calendar, among them a potential licensing agreement for its mesenchymal stem cell technology in Japan.

http://www.thelifesciencesreport.com/pub/na/imagin-a-better-way-to-detect-bladder-cancer Imagin, a Better Way to Detect Bladder Cancer - Bob Moriarty profiles Imagin Medical, a company that has developed a new way of detecting bladder cancer through endoscopes.

http://www.thelifesciencesreport.com/pub/na/regeneus-secures-government-funding-for-r-d Regeneus Secures Government Funding for R&D [RGS] - The Australian government has bolstered Regeneus, a regenerative medicine company targeting cancer, osteoarthritis and other musculoskeletal conditions, with $2.73 million in funding.

http://www.thelifesciencesreport.com/pub/na/three-shots-on-goal-in-q4-16-for-durect-corp Three Shots on Goal in Q4/16 for DURECT Corp. [DRRX] - With a trifecta of share-moving milestones anticipated in Q4/16, including possible FDA approval of abuse-resistant opioid Remoxy, Laidlaw & Co. Analyst Jim Molloy sees blue sky ahead for DURECT Corp.

http://www.thelifesciencesreport.com/pub/co/6484 Actinium Pharmaceuticals Inc. ATNM:NYSE.MKT - Discover expert commentary on Actinium Pharmaceuticals Inc. ATNM:NYSE.MKT. A snapshot of the company you cannot get anywhere else

http://www.thelifesciencesreport.com/pub/co/4634 Resverlogix Corp. RVX:TSX - Resverlogix Corp. is developing RVX-208, a first-in-class, small molecule selective BET bromodomain inhibitor for the potential treatment of patients with cardiovascular disease, diabetes mellitus, Alzheimer's disease, peripheral artery disease and chronic kidney disease.

http://www.thelifesciencesreport.com/pub/co/7294 Viveve Medical Inc. VIVE:NASDAQ - Discover expert commentary on Viveve Medical Inc. VIVE:NASDAQ. A snapshot of the company you cannot get anywhere else

http://www.thelifesciencesreport.com/pub/co/4735 Sunesis Pharmaceuticals Inc. SNSS:NASDAQ - Sunesis Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers.

http://www.thelifesciencesreport.com/pub/co/4503 DURECT Corp. DRRX:NASDAQ - Discover expert commentary on DURECT Corp. DRRX:NASDAQ. A snapshot of the company you cannot get anywhere else

Country: 69.167.183.199, North America, US

City: -84.636 Michigan, United States

Devois007 - Mini is THE stroller for 'on the go'

We bought the Mountain Buggy Mini to use as a travel stroller when we went to San Diego on family vacation (Zoo / Sea world), we found it is the PERFECT solution for quick trips out and travel (which admittedly is most of our trips to store and park). As owners of other Mountain Buggy products, we were drawn to this new compact and lightweight version. Turns out it's even easier to fold now with one hand. It also has new maintenance free tires that don't need filling, perfect for being away from home and our bike pump yet, and they work like a run flat car tire with plenty of bounce and give that other models solid wheels don't have. It weighs less than my 2 year old too, I can pop it in the trunk super easy. Like our other Mountain Buggy, it's durable enough to throw down a flight of stairs and hold up. Only regret is that it didn't include the bottle holder other strollers from Mountain Buggy do, but that's an easy accessory to pick up.

dawnablum - Straightforward and easy to use

Facing mortality was the biggest roadblock for me in using this product. Once I got past the emotional barriers, it was really just a matter of answering questions and filling in blanks. I've only completed the will up to this point, but it was no more difficult than Turbotax. My estate is pretty small and not too difficult to distribute, so definitely worth what I paid for the product

Ryan Mcadoo - Worth every penny

Worth every penny. I have had this tied up to my pier all summer and have enjoyed many drinks and laughs in it this summer.

M. Fury - Works, but a little too flimsy for my liking

If you're looking for a way to mount your Samsung U28D580D then you have limited options. This is one of them. It serves it's purpose but it's a little too flimsy for my liking. It makes the monitor top heavy and it tilts forward a bit and wobbles. The second monitor I ordered is the update (U28E590D) actually has a VESA mount. What were you thinking, Samsung, not including it on the "D" model!